Quick Answer
BeOne Medicines Ltd. reported Operating Income Loss of $447.14 million for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +178.7% in Operating Income Loss from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), BeOne Medicines Ltd.'s Operating Income Loss has grown by 2,937.7%.
- Historical annual values: Fiscal year 2025: $447.14 million | Fiscal year 2024: -$568.20 million | Fiscal year 2023: -$1.21 billion | Fiscal year 2022: -$1.79 billion | Fiscal year 2021: -$1.44 billion | Fiscal year 2020: -$1.66 billion | Fiscal year 2019: -$959.89 million | Fiscal year 2018: -$705.77 million | Fiscal year 2017: -$98.46 million | Fiscal year 2016: -$117.06 million | Fiscal year 2015: -$56.75 million | Fiscal year 2014: -$15.76 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: